Meningioma (2026): Types, Symptoms, Diagnosis and Treatment Options

Written by: Shifam Health Editorial Team — Neuro-Oncology Content Division Medically reviewed by: Shifam Health Clinical Advisory Panel Published: January 2026 | Last updated: January 2026 Sources: WHO Classification of Tumours of the Central Nervous System (5th edition, 2021), EANO guidelines, National Cancer Institute, Congress of Neurological Surgeons, peer-reviewed neurosurgery and neuro-oncology literature

Medical disclaimer: This article is for educational purposes only. It does not constitute medical advice, a diagnosis, or a treatment recommendation for any individual. Management of meningioma requires assessment by a qualified neurosurgeon, neurologist, and/or neuro-oncologist with access to your imaging and clinical information.

A meningioma is a tumour arising from the meninges — the protective membranes that surround the brain and spinal cord. Most meningiomas are slow-growing and WHO Grade 1, but some are Grade 2 (atypical) or Grade 3 (malignant) with higher recurrence risk and more aggressive behaviour. A meningioma can cause serious neurological problems depending on its size, location, and pressure on nearby structures — even when it is not technically malignant.

What Is a Meningioma?

A meningioma is a tumour that develops from cells associated with the meninges — the three-layered membrane system surrounding the brain and spinal cord. Meningiomas are the most common primary intracranial tumour type in adults, and the majority are WHO Grade 1 and slow-growing. However, a significant minority are Grade 2 or Grade 3, carry higher recurrence risk, and require more aggressive management.

Three points that patients consistently find confusing are worth addressing directly:

Is a meningioma a brain tumour? The answer depends on how you define the term. A meningioma arises from the meninges — the covering around the brain — rather than from brain tissue itself. Technically, it is extra-axial (outside the brain parenchyma). However, because it occupies space within the skull and can compress brain tissue, it is routinely classified and managed within the brain tumour specialty.

Is a meningioma cancer? Many meningiomas — particularly WHO Grade 1 — are benign in the sense that they do not invade and spread to other organs. But “benign” does not mean harmless. A Grade 1 meningioma can cause serious neurological problems if it grows in a critical location, and even completely removed Grade 1 tumours can recur. Grade 2 and Grade 3 meningiomas have genuinely aggressive biological behaviour and should not be minimised by the word “benign.”

Does every meningioma need immediate treatment? No. A meaningful proportion of meningiomas are managed with observation rather than intervention — particularly small, incidental, asymptomatic tumours in older patients. The decision depends on multiple factors discussed in this guide.

Causes and Risk Factors

Most meningiomas do not have one identifiable cause. Established risk factors include prior ionising radiation exposure, certain genetic conditions (particularly neurofibromatosis type 2), increasing age, and female sex — though the majority of patients with meningioma have none of the known major risk factors.

Established Risk Factors

What Is Not Established

Mobile phone use, head trauma, and common environmental exposures have been studied and have not been consistently established as risk factors in the scientific literature.

For most patients diagnosed with meningioma, no specific cause will be identified. The absence of an identifiable risk factor does not change the diagnosis or management approach.

Symptoms and Warning Signs

Many meningiomas — particularly small ones — cause no symptoms at all and are discovered incidentally. When symptoms do occur, they depend almost entirely on where the tumour is located and what nearby structures it is compressing or invading. There is no single symptom that is specific to meningioma.

Symptoms by Mechanism

Symptoms arise when a meningioma grows large enough to compress, displace, or invade adjacent structures:

• Headaches — often described as pressure-type, may be worse in the morning; not specific to meningioma but often what prompts imaging
• Seizures — particularly with convexity or parasagittal meningiomas near the motor cortex
• Weakness or numbness — in the limbs, if the tumour is near the motor or sensory cortex
• Vision changes — double vision, loss of peripheral vision, or visual deterioration in tumours near the optic pathways or optic nerve
• Hearing changes or tinnitus — with tumours near the eighth cranial nerve
• Balance or walking difficulties — particularly with posterior fossa or tentorial tumours
• Loss of smell — with olfactory groove meningiomas, which can grow very large before symptoms are noticed
• Memory problems or personality changes — with frontal meningiomas
• Speech difficulties — with tumours in dominant hemisphere language areas
• Hormonal abnormalities — with tumours near the pituitary or hypothalamus
• Cranial nerve symptoms — varies by nerve affected; can include facial weakness, diplopia, or swallowing difficulties

When Symptoms Require Urgent Assessment

Some symptom patterns associated with meningioma require prompt medical attention rather than a planned appointment:

• Sudden onset or rapidly worsening headache
• A new seizure in someone not previously known to have epilepsy
• Acute or rapidly progressive visual loss
• Sudden weakness, numbness, or coordination problems
• Confusion or significant personality change

These symptoms do not necessarily indicate a meningioma — many conditions can produce them — but they warrant urgent neurological evaluation.

Incidental Meningioma — Found by Accident

A substantial proportion of meningiomas are discovered incidentally — during brain MRI or CT performed for a completely unrelated reason (e.g., headache investigation, head injury assessment, or pre-operative screening). An incidental meningioma does not automatically require surgery or any active treatment.

This is one of the most important things for patients to understand. Being told you have a meningioma on a scan can feel alarming, but the discovery of an incidental tumour in someone with no relevant symptoms often changes management very little — particularly for small, radiologically typical Grade 1-appearing meningiomas in older patients.

What Happens After an Incidental Discovery?

Typically:

1. A specialist (neurosurgeon or neurologist) reviews the imaging in detail
2. The tumour’s size, location, characteristics, and relationship to nearby structures are assessed
3. A recommendation is made regarding observation versus further investigation versus treatment
4. If observation is chosen, periodic MRI is scheduled to monitor for growth

Factors That Influence the Decision

• Tumour size — small tumours are more commonly observed
• Growth rate — tumours showing no growth on serial imaging are more commonly observed
• Location — some locations are higher risk if growth occurs (e.g., near the optic nerves, brainstem)
• Imaging characteristics — features suggesting higher-grade histology influence the decision
• Symptoms — even subtle symptoms directly attributable to the tumour may prompt treatment
• Patient age and overall health — surgery and radiation carry risks that must be weighed against the natural history
• Patient preference — once risks and benefits are clearly explained

The fact that a tumour was found incidentally doesn’t make it inherently low-risk; the characteristics of the tumour determine risk, not the circumstances of its discovery.

Types of Meningioma by Location

Meningiomas can arise at many locations within the skull and along the spinal canal. Location matters because it influences which symptoms occur, how surgically accessible the tumour is, what nearby structures are at risk, and which treatment approach is most appropriate.

Common Anatomical Locations

How Meningioma Is Diagnosed

MRI with contrast is the primary imaging investigation for meningioma and provides enough information to establish a presumptive diagnosis in many cases. Definitive grading requires pathological examination of tissue obtained at surgery or biopsy but not every meningioma requires tissue confirmation before management decisions are made.

Diagnostic Pathway

Neurological examination: Assesses for deficits that localise to the tumour’s anatomical location.

MRI with gadolinium contrast: The main imaging investigation. Typically reveals an extra-axial (outside the brain) enhancing mass with characteristic features (see Section 7).

CT scan: May be useful when:

• Bone involvement or hyperostosis (bone thickening) is being assessed
• Calcification within the tumour is relevant to surgical planning
• Emergency assessment is needed
• MRI is contraindicated

Additional imaging: In selected cases, CT angiography or conventional angiography may assess the tumour’s blood supply (particularly in large, vascular tumours) or the relationship to venous sinuses.

Pathological examination: Performed when tissue is obtained — at surgery, or rarely via standalone biopsy. Provides definitive WHO grading and molecular characterisation. For a radiologically typical small meningioma being managed with observation, biopsy is not routinely performed.

When Is Biopsy Performed Without Surgery?

Standalone stereotactic biopsy is occasionally performed when:

• The diagnosis is radiologically uncertain
• The patient cannot undergo open surgery
• Treatment planning requires tissue for grading (e.g., before radiation)

What a Meningioma Looks Like on MRI

On MRI, meningiomas typically appear as extra-axial (outside the brain) masses that enhance brightly and uniformly after contrast injection, are broadly attached to the dura (dural base), and may show a “dural tail” — a thin enhancement extending along the adjacent dura. These features are characteristic but not invariably diagnostic.

Typical MRI Characteristics

Important Caveat

These features are strongly suggestive of meningioma, but other lesions can sometimes have overlapping appearances — including dural metastases, solitary fibrous tumours, and other extra-axial tumours. Radiological diagnosis is presumptive; definitive diagnosis requires pathological confirmation when tissue is obtained.

Patients should not attempt to interpret their own MRI images. A neuroradiologist’s formal report, interpreted in clinical context by a neurosurgeon or neurologist, is how imaging findings are translated into medical decisions.

Pathology, WHO Grading, and Molecular Classification

Meningiomas are classified by the World Health Organization (WHO) into three grades based on histological features and molecular characteristics. Grade reflects biological aggressiveness and recurrence risk — not anatomical spread. The 2021 WHO CNS5 classification introduced important changes to grading criteria, particularly incorporating specific molecular alterations.

WHO Grade Overview

Grade Is Not Stage

This distinction is fundamental and frequently misunderstood. Stage (as used in many cancer types) describes how far a cancer has spread beyond its origin. Grade describes the histological and molecular characteristics of the tumour tissue — its biological behaviour. A Grade 1 meningioma that is very large and surgically inaccessible may be far more clinically challenging than a small Grade 3 tumour in an accessible location.

2021 WHO CNS5 — What Changed

The 2021 WHO Classification of Tumours of the Central Nervous System introduced significant updates to meningioma grading:

• CDKN2A/B homozygous deletion now confers Grade 3 classification regardless of histological features — patients whose tumours show this molecular alteration are classified as Grade 3 even if the tissue does not look like a Grade 3 meningioma under the microscope
• TERT promoter mutation in combination with certain histological features similarly influences grading
• These changes mean that a tumour that would have been classified as Grade 2 under older criteria may now be classified as Grade 3, and a tumour that appeared histologically benign may be upgraded based on molecular findings

Molecular Alterations in Meningioma

Beyond grading, molecular analysis of meningiomas has identified several recurrently altered genes with clinical relevance:

Molecular testing of meningioma tissue is not universally performed but is increasingly relevant for grading accuracy (particularly in Grade 2/3 cases), treatment planning in recurrent disease, and clinical trial eligibility.

Does Every Meningioma Need Treatment?

No. Many meningiomas — particularly small, incidental, asymptomatic, or very slow-growing tumours in older or medically frail patients — are appropriately managed with observation rather than immediate surgery or radiation. The decision involves weighing the risks of intervention against the natural history of the specific tumour in the individual patient.

When Observation May Be Appropriate

• Small tumour with no symptoms attributable to it
• Radiologically typical Grade 1 appearance
• No growth on initial follow-up imaging
• Older patient for whom surgery carries higher risk
• Tumour in a location where growth over time poses low immediate threat
• Patient preference after full information about risks and alternatives

When Active Treatment Is More Likely to Be Recommended

• Symptomatic tumour (seizures, neurological deficit, vision changes)
• Documented growth on serial imaging
• Large tumour with significant mass effect
• Oedema (swelling of adjacent brain) suggesting pressure effect
• High-risk location (e.g., threatening optic pathways, brainstem, major sinuses)
• Imaging characteristics suggesting higher-grade histology
• Younger patient where long-term natural history is more consequential

The boundary between these categories is not sharp, and individual cases often fall in between — which is why multidisciplinary specialist assessment is essential.

Observation and MRI Surveillance

Active surveillance also called watchful waiting or observation involves periodic MRI to monitor tumour size and characteristics without immediate intervention. It is a legitimate, guideline-supported management option for selected meningiomas, not a passive failure to treat.

What Surveillance Involves

• Scheduled MRI scans at intervals determined by the treating team, usually more frequent initially and less frequent once stability is established
• Neurological review to assess for new or changing symptoms
• Ophthalmological review if the tumour is near visual pathways
• Endocrine assessment where the tumour is near pituitary/hypothalamic structures

What Triggers a Reassessment

Surveillance is not passive. Any of the following typically triggers re-evaluation of the management plan:

• Documented tumour growth on follow-up MRI
• Development of new symptoms
• Worsening of existing symptoms
• Change in imaging characteristics
• Development of oedema
• Increasing mass effect on adjacent structures

What Patients Should Understand About Surveillance

Being on a surveillance program does not mean the tumour is being ignored — it means the balance of risks has been assessed and the risks of intervention currently outweigh the risks of the tumour’s current behaviour. This balance can change over time, which is why follow-up imaging is essential.

Missing surveillance scans — particularly in the first few years after diagnosis — removes the ability to detect meaningful change before it becomes a neurological emergency.

Surgery

Surgery is the primary treatment for meningiomas that are symptomatic, growing, or large enough to pose risk to adjacent structures. The surgical goal is maximal safe resection — removing as much tumour as possible while preserving neurological function and avoiding damage to adjacent critical structures.

What Surgery Achieves

• Tissue diagnosis and definitive WHO grading
• Removal of tumour mass, reducing or eliminating pressure on the brain
• Relief of symptoms caused by compression
• Reduction or elimination of oedema
• Potential long-term control, particularly after complete resection of Grade 1 tumours
• Cytoreduction (volume reduction) before or after radiation in higher-grade disease

Maximal Safe Resection — Not Maximum Removal at Any Cost

The principle that guides meningioma surgery is removing as much tumour as safely possible, not simply removing as much as technically possible. When a meningioma is attached to a major venous sinus, wrapping around a cranial nerve, or adherent to a major artery, attempting complete removal risks devastating neurological injury. In these situations, intentional subtotal resection — leaving a remnant to avoid harm — is not a failure. It is the correct surgical decision.

Extent of Resection — Simpson Grading

The Simpson grading scale (Grades 1–5) has historically been used to describe the completeness of meningioma resection, with Grade 1 representing complete removal including the dural attachment and Grade 5 representing biopsy only. While still referenced in the literature, Simpson grading is now understood in context: the relationship between extent of resection and recurrence risk is substantially influenced by WHO grade and molecular features — a completely resected Grade 2 or 3 meningioma has a higher recurrence risk than a subtotally resected Grade 1 tumour.

Types of Surgical Approach

The surgical approach depends entirely on tumour location. Common approaches include:

• Craniotomy — most common; a section of skull is temporarily removed to access the tumour
• Endoscopic-assisted surgery — used in selected skull-base locations
• Transpetrosal, orbitozygomatic, and other skull-base approaches — specialist techniques for deep or laterally positioned tumours

What Patients Should Expect After Surgery

Hospital stays vary by procedure complexity — typically several days to a week for routine craniotomy, potentially longer for complex skull-base surgery. Steroid medication is routinely used to manage post-operative brain swelling. Post-operative MRI assesses completeness of resection.

Skull-Base and High-Risk Location Meningiomas

Skull-base meningiomas present the greatest surgical challenges because of their proximity to cranial nerves, major blood vessels, the brainstem, and visual pathways. Treatment requires specialist expertise and is increasingly managed with multidisciplinary approaches — often combining surgery with radiosurgery or fractionated radiation rather than surgical resection alone.

Why Skull-Base Location Matters

The skull base — the floor of the cranial vault — contains the most important neural and vascular structures in the central nervous system, including:

• The optic nerves and chiasm
• The cavernous sinus and its cranial nerve contents (cranial nerves III, IV, V, VI)
• The carotid arteries and basilar artery
• The brainstem
• Multiple cranial nerve exit foramina

A meningioma at any of these locations places these structures at risk both from tumour growth and from any surgical attempt to remove it.

Management Approach for Skull-Base Tumours

The approach is individualised and may include any combination of:

• Surgery — for tumour accessible to resection without unacceptable risk; maximal safe debulking
• Stereotactic radiosurgery — for small to medium residual tumour away from radiation-sensitive structures
• Fractionated radiation — for larger tumours or those immediately adjacent to structures that cannot safely receive radiosurgery doses in a single fraction
• Observation — for small, asymptomatic skull-base tumours in selected patients

Optic Nerve Sheath Meningiomas

A specific and important subset — meningiomas arising from the sheath of the optic nerve itself. Surgery risks optic nerve damage, so radiation therapy (fractionated stereotactic radiotherapy) is frequently the preferred active treatment when intervention is needed, as it can sometimes stabilise or improve vision while controlling tumour growth. Management decisions require close collaboration between neurosurgery, neuro-ophthalmology, and radiation oncology.

Stereotactic Radiosurgery — Gamma Knife and CyberKnife

Stereotactic radiosurgery delivers a very high, precisely focused dose of radiation to a defined target in one session (or sometimes a small number of sessions), without a surgical incision. Despite the word “surgery” in its name, it is a radiation treatment. Gamma Knife and CyberKnife are the most widely known radiosurgery platforms, differing in technology and delivery but sharing the same underlying principle.

What Radiosurgery Offers

• Non-invasive (no incision, no anaesthesia required for the radiation delivery)
• Treatment typically completed in one day or over a small number of sessions
• Appropriate for selected tumours that surgery cannot safely address
• Can treat residual tumour after surgery
• Can be used as primary treatment for small to medium meningiomas in selected locations
• Has a well-established track record for selected skull-base and convexity meningiomas

Gamma Knife vs CyberKnife — Key Differences

What matters most in practice: The choice between platforms is less important than the experience of the treating radiation oncology team and the quality of treatment planning. An expert team on a standard platform consistently outperforms an inexperienced team using the most technologically advanced equipment.

When Radiosurgery Is and Is Not Appropriate

May be appropriate: Small to medium meningiomas (typically under 3 cm, though varies); tumours with well-defined margins; residual post-operative tumour; patients not suitable for open surgery; selected skull-base tumours not adjacent to the optic pathway.

May not be appropriate: Large tumours (insufficient margin from critical structures for the required dose); tumours immediately adjacent to the optic pathway (optic nerves and chiasm are sensitive to high single doses); tumours producing significant mass effect requiring surgical decompression; Grade 3 disease where more aggressive multimodal treatment is typically required.

Fractionated Radiation Therapy and Proton Therapy

Fractionated radiation therapy — delivering radiation in multiple smaller doses over several weeks — is used when the tumour is too large for single-session radiosurgery, too close to radiation-sensitive structures, or when higher-grade disease requires postoperative radiation. Proton therapy is a radiation modality that may reduce dose to surrounding healthy tissue in selected cases.

When Fractionated Radiation Is Used

• Large tumours where dose constraints for radiosurgery cannot be met
• Tumours immediately adjacent to the optic pathway where fractionation is safer than a single high dose
• Postoperative radiation after incomplete resection of Grade 2 or Grade 3 meningioma
• Selected recurrent tumours after prior surgery

Conventional Fractionated Radiotherapy vs Stereotactic Fractionated Radiotherapy

Standard fractionated radiation and stereotactic fractionated radiotherapy (SFRT) use the same principle but differ in the number of fractions and precision of delivery. SFRT combines the precision of radiosurgery with the radiobiological advantages of fractionation — useful for larger or critically located tumours.

Postoperative Radiation for Grade 2 and Grade 3

This is one of the most contested management questions in meningioma:

Grade 3: Postoperative radiation is generally recommended given the high recurrence risk, though evidence from randomised trials is limited and treatment approaches are guided by expert consensus and individual centre experience.

Grade 2: The decision is more nuanced. Following complete resection, practice varies between centres — some recommend observation with close MRI follow-up; others recommend adjuvant radiation particularly after incomplete resection. Current EANO and other guidelines reflect this uncertainty. The decision requires multidisciplinary discussion incorporating grade, extent of resection, molecular features, and patient factors.

Proton Therapy

Proton therapy delivers radiation using protons rather than X-rays, with a physical property (the Bragg peak) that allows more precise dose deposition with less exit dose to surrounding tissue.

When proton therapy may be considered:

• Skull-base tumours in close proximity to critical structures where dose reduction to normal tissue is important
• Re-irradiation (second course of radiation) where prior radiation limits further X-ray-based dose
• Younger patients where long-term radiation effects to surrounding brain are a concern

Proton therapy does not inherently improve tumour control or survival compared with other high-quality radiation planning. Its advantage is in potentially reducing dose to adjacent critical structures. Availability is more limited than LINAC-based systems, and not all patients who could theoretically benefit have access or meet selection criteria.

Recurrent Meningioma

Meningioma can recur after surgery, after radiation, or during observation — with recurrence risk substantially influenced by WHO grade, extent of initial resection, molecular features, and tumour location. Recurrent meningioma is a distinct clinical challenge requiring reassessment rather than simply repeating the initial treatment.

Recurrence Risk by Grade

Recurrence risk is grade-dependent. Published studies consistently show that higher-grade tumours have substantially higher recurrence rates than Grade 1 tumours, and that incompletely resected tumours of any grade have higher recurrence rates than completely resected ones. Presenting specific recurrence percentages as universal would be misleading, as these depend on follow-up duration, patient selection, and treatment era and outcomes with modern management continue to evolve.

Management Options for Recurrent Disease

What Recurrence Does Not Mean

Recurrence does not automatically mean the original treatment failed. Many Grade 2 and Grade 3 meningiomas recur eventually despite optimal initial treatment — this reflects the biology of the tumour, not a treatment error. Management of recurrence should involve multidisciplinary reassessment.

Systemic Treatment for Advanced or Recurrent Disease

Unlike many cancers, meningioma does not have an established standard chemotherapy or systemic drug regimen. Conventional cytotoxic chemotherapy has shown limited effectiveness. Selected agents are used off-label or in clinical trials for patients with unresectable, recurrent, or progressive higher-grade meningiomas.

Current Evidence

The systemic treatment landscape for meningioma in 2026 reflects a field where standard options are limited and clinical trial participation is encouraged for appropriate patients:

• Bevacizumab (anti-VEGF antibody): Has been used off-label in progressive or recurrent meningioma, showing modest evidence of radiological stabilisation in some studies. Not standard care; used when other options are exhausted.
• Somatostatin analogues (e.g., octreotide, pasireotide): Explored because meningiomas often express somatostatin receptors; results have been modest.
• VEGFR/PDGFR tyrosine kinase inhibitors: Studies with agents like sunitinib have shown limited results in recurrent meningioma.
• mTOR pathway inhibitors: Investigated in NF2-related and sporadic meningiomas; ongoing research.
• Immune checkpoint inhibitors: Under investigation in clinical trials; not established standard therapy.
• Molecularly targeted therapy: Emerging area — SMO inhibitors, AKT inhibitors, and others are being studied in molecularly selected meningiomas. Results are still maturing.

Transparency statement: None of the above agents represent established standard care for meningioma in the same way that chemotherapy regimens do for other cancers. Patients with recurrent or progressive Grade 2/3 meningioma for whom surgery and radiation options are exhausted should discuss clinical trial eligibility with their neuro-oncologist.

Prognosis, Recurrence Risk, and Follow-Up

Prognosis in meningioma is profoundly grade-dependent. WHO Grade 1 meningiomas, particularly when completely resected, generally carry a favorable outlook. Grade 2 meningiomas have meaningfully higher recurrence rates and require closer monitoring. Grade 3 meningiomas have an aggressive course with high recurrence risk and require sustained multimodal management.

What Determines Prognosis

• WHO grade — the single strongest pathological determinant
• Molecular features — CDKN2A/B deletion and TERT promoter mutation are associated with worse outcomes
• Extent of surgical resection — complete resection generally reduces (but does not eliminate) recurrence risk
• Tumour location — surgically inaccessible locations make complete resection harder to achieve
• Prior recurrence — recurrent tumours often have a more aggressive course
• Age and overall health — influence treatment tolerance and outcomes
• Postoperative radiation — in Grade 2/3, reduces local recurrence rates in most studies

Why Individual Prognosis Cannot Be Stated as a Single Number

Published survival and recurrence statistics for meningioma come from heterogeneous patient populations, vary by treatment era, and reflect different definitions of recurrence. A blanket statement such as “the 5-year recurrence rate is X%” is not clinically meaningful for an individual patient — it may substantially over- or underestimate their specific risk. An oncologist familiar with the patient’s pathology, molecular profile, extent of resection, and imaging can give much more useful (though still uncertain) prognostic guidance.

Long-Term Follow-Up

All patients with meningioma — regardless of WHO grade or treatment — require ongoing surveillance:

• Periodic MRI (frequency determined by grade, treatment, and individual risk)
• Neurological review
• Ophthalmological assessment where the tumour is near visual pathways
• Endocrine monitoring where the tumour is near the pituitary
• Higher-grade tumours typically require more frequent and prolonged follow-up

The frequency of follow-up MRI is not uniform — it is adjusted based on tumour grade, treatment history, and whether the tumour has shown prior growth or recurrence.

Meningioma and Hormones

Meningiomas occur approximately twice as commonly in women as in men, and many meningiomas express hormone receptors particularly progesterone receptors. Epidemiological observations and case reports have noted that meningiomas can sometimes grow during pregnancy or with hormonal therapy, but the relationship is complex and does not imply that hormonal treatments directly cause meningioma in most patients.

What the Evidence Shows

• Meningiomas frequently express progesterone receptors (PR), and some express oestrogen receptors (ER)
• Population studies have found associations between certain hormonal medications (particularly high-dose progestins used for contraception or uterine conditions — cyproterone acetate, chlormadinone acetate, medroxyprogesterone acetate) and elevated meningioma risk; this has prompted regulatory action in some countries
• Pregnancy can be associated with accelerated meningioma growth in some patients, likely related to hormonal and physiological changes
• Standard low-dose oral contraceptives and postmenopausal hormone replacement therapy have not been consistently established as major risk factors in the general literature

Meningioma in Pregnancy

If a meningioma is detected during pregnancy, management requires balancing:

• The urgency of the mother’s neurological situation
• The stage of pregnancy and risks of any intervention
• Whether symptoms are mild and stable or rapidly progressive

Most meningiomas discovered in pregnancy are managed conservatively until after delivery if the neurological situation permits. Cases with rapid deterioration may require intervention during pregnancy — a decision made by a multidisciplinary team including neurosurgery, neuro-oncology, and obstetrics.

What Patients Should NOT Do

Do not stop hormonal contraception, hormone replacement therapy, or any other prescribed medication based on reading about meningioma and hormones without first discussing this with the prescribing physician and a neurosurgeon or neurologist familiar with your case. The risk-benefit calculation is individual.

Meningioma Treatment Cost in India

Meningioma treatment cost in India varies substantially based on the management approach — observation involves periodic MRI costs, surgery involves surgical and hospitalization costs, radiosurgery has its own cost structure, and higher-grade disease requiring multimodal treatment is more expensive. No single figure applies to all patients.

Cost by Management Approach (Approximate Ranges for International Patients)

The following ranges are for general orientation only. International patient pricing is typically higher than domestic Indian pricing. Always request a hospital-specific cost estimate based on your actual imaging and treatment plan.

Observation (watchful waiting):

• MRI scans: approximately USD 200–500 per scan at major hospitals
• Neurological consultation: approximately USD 50–150 per visit
• Cost is ongoing over years of surveillance

Surgery (craniotomy for meningioma):

• Surgical procedure, anaesthesia, ICU, hospitalisation: approximately USD 5,000–15,000+ depending on complexity
• Skull-base surgery or complex procedures may cost significantly more (USD 12,000–25,000+)
• Post-operative MRI and consultations add to this

Stereotactic radiosurgery (Gamma Knife / CyberKnife):

• Single-session radiosurgery: approximately USD 4,000–9,000 at major centres
• Hypofractionated courses (multiple sessions): higher cost

Fractionated radiation therapy:

• Full course of fractionated radiotherapy: approximately USD 4,000–10,000 depending on fractions and technique
• Proton therapy (where available): higher cost

Pathology and molecular testing:

• Standard neuropathology: included in surgical costs at most centres
• Extended molecular/NGS panel: additional USD 500–2,000

Verification note: These ranges are approximate and based on available published information. They should be treated as orientation only. Hospital-specific estimates — based on reviewing the patient’s actual MRI and medical records — are the only reliable source of cost information.

Choosing a Meningioma Treatment Centre

For meningioma — particularly complex skull-base tumours, high-grade disease, and recurrent cases — the quality of the treating team and the centre’s multidisciplinary capabilities matter more than general hospital reputation or ranking. Key capabilities determine whether a centre is appropriate for a given patient’s case.

What a Suitable Centre Should Have

International Patient Coordination Checklist

For patients considering meningioma treatment in India:

1. Share MRI and all available imaging (CD/digital files) with the hospital’s international patient department
2. Share any available pathology reports if tissue has been obtained previously
3. Neurosurgical and neuro-oncology review of records
4. Multidisciplinary team recommendation
5. Formal cost estimate based on treatment plan
6. Hospital invitation letter for medical visa (see Indian Medical Visa Guide)
7. Travel and accommodation planning
8. Surgery / radiation / observation commencement
9. Post-treatment MRI and review
10. Detailed treatment summary and follow-up plan for home physicians
11. Telemedicine follow-up coordination

Frequently Asked Questions

Ready to Discuss Your Meningioma Case?

If you have been diagnosed with a meningioma and are exploring treatment options in India, or seeking a specialist review of your imaging before making any decision, the first step is sharing your MRI and medical records with a neurosurgical or neuro-oncology team for assessment.

Shifam Health coordinates:

• MRI and medical record sharing with neurosurgical and neuro-oncology specialists
• Multidisciplinary treatment recommendation
• Cost estimate facilitation
• Medical visa documentation assistance (see our Medical Visa guide)
• Travel, accommodation, and arrival coordination
• Post-treatment follow-up communication

Related Reads:

• Brain Tumor Treatment in India
• Neurosurgery Hospitals in India
• Best Neurosurgeons in India
• Gamma Knife Surgery in India
• CyberKnife Radiosurgery India
• Proton Therapy in India
• Cancer Treatment Cost in India
• Indian Medical Visa Guide
• Emergency Medical Visa India
• Stereotactic Radiosurgery for Brain Tumors India
• Medical Tourism in India